至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Lack of Heterologous Cross-reactivity toward HLA-A*02:01 Restricted Viral Epitopes Is Underpinned by Distinct αβT Cell Receptor Signatures.

J. Biol. Chem.. 2016-09; 
GrantEmma J,JosephsTracy M,ValkenburgSophie A,WooldridgeLinda,HellardMargaret,RossjohnJamie,BharadwajMandvi,KedzierskaKatherine,GrasSteph
Products/Services Used Details Operation
Peptide Synthesis The following HLA-A*02:01-restricted peptides were purchased from Genscript: HCV-NS31073–1081 and variant peptides (CINGVCWTV; CVNGVCWTV), influenza-NA231–239 WT and variant peptides (CVNGSCFTV; CVNGSCFTI; CINGSCFTI; CINGTCTVV), influenza-M158–66 (GILGFVFTL), and BMLF-1 (GLCTLVAML). Get A Quote

摘要

αβT cell receptor (TCR) genetic diversity is outnumbered by the quantity of pathogenic epitopes to be recognized. To provide efficient protective anti-viral immunity, a single TCR ideally needs to cross-react with a multitude of pathogenic epitopes. However, the frequency, extent, and mechanisms of TCR cross-reactivity remain unclear, with conflicting results on anti-viral T cell cross-reactivity observed in humans. Namely, both the presence and lack of T cell cross-reactivity have been reported with HLA-A*02:01-restricted epitopes from the Epstein-Barr and influenza viruses (BMLF-1 and M1, respectively) or with the hepatitis C and influenza viruses (NS3 and NA, respectively). Given the high s... More

关键词

Epstein-Barr virus,Hepatitis C virus (HCV),Human Leukocyte Antigen,T cell immunity,cellular immune response,influenza virus,lymphocyte,major histocompatibility complex (MHC),viral immuno